doranidazole has been researched along with Pancreatic Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hosotani, R; Karasawa, K; Matsui, K; Matsuno, S; Nemoto, K; Nishimura, Y; Ogata, Y; Okamoto, A; Sunamura, M | 1 |
| Kishii, K; Kobayashi, A; Kubota, N; Masui, S; Yahiro, T; Yamada, K | 1 |
| Karasawa, K; Matsuno, S; Nemoto, K; Nishimura, Y; Okamoto, A; Shibamoto, Y; Sunamura, M | 1 |
| Kishii, K; Kubota, T; Shibamoto, Y; Tsujitani, M | 1 |
| Kura, S; Mizumoto, K; Nagai, E; Qian, LW; Tanaka, M; Zhang, L | 1 |
2 trial(s) available for doranidazole and Pancreatic Neoplasms
| Article | Year |
|---|---|
Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Humans; Imidazoles; Intraoperative Period; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Analysis | 2004 |
Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study.
Topics: Adult; Aged; Cell Hypoxia; Female; Humans; Imidazoles; Intraoperative Period; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Rate | 2008 |
3 other study(ies) available for doranidazole and Pancreatic Neoplasms
| Article | Year |
|---|---|
Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Radiation; Humans; Imidazoles; Mice; Oxygen; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents | 2005 |
Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole.
Topics: Animals; Cell Survival; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Pancreas; Pancreatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Reference Values; Sensitivity and Specificity; Tumor Cells, Cultured; Whole-Body Irradiation | 2000 |
A nitroimidazole derivative, PR-350, enhances the killing of pancreatic cancer cells exposed to high-dose irradiation under hypoxia.
Topics: Cell Death; Cell Hypoxia; DNA, Neoplasm; Humans; Imidazoles; Pancreatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2002 |